Counterfeits are indistinguishable to the naked eye
Modern counterfeiters replicate holograms, serial numbers, and security inks with alarming accuracy. Traditional physical security features no longer provide meaningful protection.
YOUR CHALLENGE
Modern counterfeit medicines are winning.
The tools to stop them haven't kept up.
Pharmaceutical brands are fighting an increasingly sophisticated threat with tools designed for a different era. TrueMed was built to change that.
1 in 10
Medical products in developing markets are substandard or falsified (WHO)
$200B+
Annual cost of counterfeit pharmaceuticals to the global industry
≤48hrs
Time it takes TrueMed to go from artwork file to active protection
The Problem
The biggest counterfeit drug detection challenges facing pharmaceutical companies.
Today's counterfeit threats move faster than traditional anti-counterfeit technologies. These four challenges make it harder for pharmaceutical companies to detect counterfeit medicines, respond quickly, and prevent future incidents.
Traditional lab testing is too slow
By the time a suspect product reaches the lab and results come back, counterfeit product has already moved through the supply chain. Days or weeks of delay means patients are already at risk.
Detection data never builds into intelligence
Every scan, every case, every field report generates data, but with no shared system to capture it, none of it compounds. You're starting from zero on every investigation instead of getting smarter with each one.
Investigations are siloed
Quality, legal, and supply chain teams work independently, and the patterns that could predict the next attack go undetected.
The Trend
The global counterfeit medicine threat is accelerating.
Digital printing, global e-commerce, and weakened supply chains post-pandemic have created conditions where counterfeit medicines have never been easier to produce or distribute at scale.
Rise in reported counterfeit medicine seizures between 2020 and 2023 (Interpol)
Estimated global economic cost of counterfeiting across all sectors by 2022 (OECD)
Of counterfeit medicines seized in Sub-Saharan Africa contain no active ingredient at all
Faster replication rate for counterfeit packaging since AI-assisted workflows became accessible
Why Traditional Anti-Counterfeit Technologies Fail
Most anti-counterfeit technologies solve yesterday's problem.
While the pharmaceutical industry has invested billions in holograms, security inks, serialization, and laboratory testing, counterfeiters have adapted just as quickly. The tools were never the problem. The model was.
Holograms & security inks
Counterfeiters have replicated every physical security feature to market within 12–18 months of release. What was cutting-edge becomes a false signal of trust.
Lab-based testing
Requires physical sample shipping across borders. Results arrive in days or weeks, long after the suspect product has moved through the supply chain and reached patients.
Serialisation & track-and-trace
Effective for diversion detection, but serial numbers can be cloned. Doesn’t verify what’s inside the pack and relies on infrastructure most markets don’t have.
Consumer reporting lines
Passive and reactive. Patients rarely report, and when they do, products have long since been consumed. Data is anecdotal, not actionable intelligence.
The Stakes
Doing nothing is costly. Choosing the wrong solution can be just as expensive.
Pharmaceutical companies face a double bind: failing to detect counterfeit medicines puts patients, brands, and revenue at risk, while many legacy anti-counterfeit technologies require significant investment without delivering meaningful long-term protection.
Cost of Inaction
Patient harm
Counterfeit medicines kill an estimated 100,000–250,000 people annually in Africa alone. Each incident that goes undetected is a preventable death.
Revenue erosion
Every counterfeit unit sold is a lost sale and erodes the price premium your brand commands. Counterfeits in the market suppress your legitimate volume.
Brand destruction
A single high-profile counterfeit incident can wipe years of brand equity. Recall events, media coverage, and loss of prescriber confidence compound rapidly.
Regulatory exposure
Regulators increasingly expect brands to demonstrate active monitoring. Failure to detect counterfeits has resulted in warning letters and market suspensions.
Cost of Wrong Action
Packaging overhaul
Physical security features require changes to packaging artwork, print specifications, and manufacturing lines that trigger regulatory resubmission in every affected market.
Per-unit cost at scale
Serialisation overlays, hologram labels, and smart packaging add marginal cost per unit that compounds into tens of millions annually across a full portfolio.
18-month implementation cycles
By the time a new physical feature is designed, approved, and rolled out globally, counterfeiters have already analyzed them, limiting both their lifespan and long-term value.
No intelligence value
Physical features tell you a product was scanned, not where the threat is concentrated, which strains are emerging, or which routes carry the highest risk.